Ratings Valneva

Equities

VLA

FR0004056851

Market Closed - Euronext Paris Other stock markets 11:35:21 2024-05-06 am EDT			5-day change	1st Jan Change
3.418 ^EUR	-0.47%		-0.75%	-27.58%

Apr. 11	Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	CF
Mar. 26	Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
VALNEVA	-27.58%	513M	B-
MODERNA, INC.	+22.81%	47.9B	B-
LONZA GROUP AG	+46.56%	41.42B	A
IQVIA HOLDINGS INC.	-1.88%	40.7B	B
CELLTRION, INC.	-6.20%	28.92B	C
ICON PUBLIC LIMITED COMPANY	+11.33%	25.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.27B	B
BIO-TECHNE CORPORATION	-1.43%	12.15B	B+
MEDPACE HOLDINGS, INC.	+30.73%	12.14B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.48%	11.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes